Time-dependent interaction of ritonavir in chronic use: The power balance between inhibition and induction of P-glycoprotein and cytochrome P450 3A

被引:12
作者
Fukushima, Keizo [1 ]
Kobuchi, Shinji [2 ]
Mizuhara, Kazunori [2 ]
Aoyama, Hiroaki [2 ]
Takada, Kanji [2 ]
Sugioka, Nobuyuki [1 ]
机构
[1] Kobe Gakuin Univ, Fac Pharmaceut Sci, Dept Clin Pharmacokinet, Chuo Ku, Kobe, Hyogo 6508586, Japan
[2] Kyoto Pharmaceut Univ, Dept Pharmacokinet, Yamashina Ku, Kyoto 6078412, Japan
关键词
ADME; bioavailability; cytochrome P450; disposition; drug interaction; intestinal absorption; P-glycoprotein; pharmacokinetics; LOPINAVIR/RITONAVIR; RATS; PHARMACOKINETICS; METABOLISM; EFFICACY; SAFETY; RHODAMINE-123; ATAZANAVIR; MIDAZOLAM; PROTEASE;
D O I
10.1002/jps.23545
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Ritonavir (RTV) is not only an inhibitor but also an immunoreactive inducer of both P-glycoprotein (Pgp) and cytochrome P450 (CYP) 3A in terms of its chronic use. The aim of present study was to test the hypothesis that the power balance between inhibition effects of RTV and induced activities of Pgp and CYP3A depends on the time after last RTV treatment (TimeR) in the chronic use of RTV; rhodamine 123 (Rho) and midazolam (MDZ) were administered at predetermined TimeR to rats pretreated with RTV for 7 days. After oral administration of Rho and MDZ to rats pretreated with RTV for 7 days, the areas under the plasma concentrationtime curve of Rho and MDZ were significantly altered depending on TimeR: 1.27-, 0.79-, 0.95-, and 0.11-fold increases over that of the control for Rho at TimeR = 0, 3, 9, and 24 h and 3.12-, 1.50-, 1.27-, and 0.17-fold increases over that of the control for MDZ at TimeR = 0, 3, 9, and 24 h, respectively. These results revealed the presence of the time-dependent interaction of RTV with concomitant drugs in chronic use and should be taken into account in therapeutic strategies for HIV infection. (c) 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 102:20442055, 2013
引用
收藏
页码:2044 / 2055
页数:12
相关论文
共 27 条
[1]   Contribution of Rat Pulmonary Metabolism to the Elimination of Lidocaine, Midazolam, and Nifedipine [J].
Aoki, Makoto ;
Okudaira, Kazuho ;
Haga, Makoto ;
Nishigaki, Ryuichiro ;
Hayashi, Masahiro .
DRUG METABOLISM AND DISPOSITION, 2010, 38 (07) :1183-1188
[2]   Unmasking the dynamic interplay between efflux transporters and metabolic enzymes [J].
Benet, LZ ;
Cummins, CL ;
Wu, CY .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2004, 277 (1-2) :3-9
[3]   Efficacy, safety and pharmacokinetics of 900/100 mg of darunavir/ritonavir once daily in treatment-experienced patients [J].
Curran, Adrian ;
Gutirerrez, Mar ;
Deig, Elisabet ;
Mateo, Gracia ;
Maria Lopez, Rosa ;
Imaz, Arkaitz ;
Crespo, Manuel ;
Ocana, Inma ;
Domingo, Pere ;
Ribera, Esteban .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (10) :2195-2203
[4]   Long-term pharmacokinetic efficacy and safety of low-dose ritonavir as a booster and atazanavir pharmaceutical formulation based on solid dispersion system in rats [J].
Fukushima, Keizo ;
Haraya, Kenta ;
Terasaka, Shuichi ;
Ito, Yukako ;
Sugioka, Nobuyuki ;
Takada, Kanji .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2008, 31 (06) :1209-1214
[5]   Dose-dependent intestinal and hepatic first-pass metabolism of midazolam, a cytochrome P450 3A substrate with differently modulated enzyme activity in rats [J].
Higashikawa, F ;
Murakami, T ;
Kaneda, T ;
Kato, A ;
Takano, M .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1999, 51 (01) :67-72
[6]   Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects [J].
Hogeland, G. W. ;
Swindells, S. ;
McNabb, J. C. ;
Kashuba, A. D. M. ;
Yee, G. C. ;
Lindley, C. M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (01) :69-75
[7]   Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures [J].
Johnson, M ;
Grinsztejn, B ;
Rodriguez, C ;
Coco, J ;
DeJesus, E ;
Lazzarin, A ;
Lichtenstein, K ;
Rightmire, A ;
Sankoh, S ;
Wilber, R .
AIDS, 2005, 19 (07) :685-694
[8]   Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers [J].
Kageyama, M ;
Fukushima, K ;
Togawa, T ;
Fujimoto, K ;
Taki, M ;
Nishimura, A ;
Ito, Y ;
Sugioka, N ;
Shibata, N ;
Takada, K .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (04) :779-784
[9]   In vivo effects of cyclosporin A and ketoconazole on the pharmacokinetics of representative substrates for P-glycoprotein and cytochrome P450 (CYP) 3A in rats [J].
Kageyama, M ;
Namiki, H ;
Fukushima, H ;
Ito, Y ;
Shibata, N ;
Takada, K .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (02) :316-322
[10]   Effect of chronic administration of ritonavir on function of cytochrome P450 3A and P-glycoprotein in rats [J].
Kageyama, M ;
Namiki, H ;
Fukushima, H ;
Terasaka, S ;
Togawa, T ;
Tanaka, A ;
Ito, Y ;
Shibata, N ;
Takada, K .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2005, 28 (01) :130-137